Maxvolt Energy ----------------- Small steps.... Source - Linkedin

#venusremedies Is Venus Remedies a boring 15–20% compounder quietly doing hospital supply rounds — or a deeply misunderstood asymmetric bet hiding behind a pharma label nobody bothers to read? 🧵 The business Venus Remedies is not your typical pharma company grinding out generic tablets for retail chemists. It operates in a niche that most investors walk past: sterile injectable formulations for hospital ICUs — antibiotics that fight drug-resistant superbugs, chemotherapy injectables, and critical care drugs that can only be delivered intravenously in a controlled clinical setting. For nearly a decade the company struggled — good science, poor commercialisation, heavy debt. Then management made two pivots that changed everything: they stopped selling complex molecules directly, instead signing manufacturing alliances with Cipla, Zydus, and Intas who already owned hospital relationships. And they cleared every rupee of debt from operating cash flow. Today Venus runs a debt-free balance sheet with ₹250 Cr in unencumbered cash — while its sterile lines run at near-full capacity. The moat — especially the IP layer Two-layer moat. The outer wall: 1,000 global Marketing Authorisations(license to sell medicines) tied to specific plants, non-transferable, each taking 18–36 months to secure. Any competitor replicating Venus's export footprint needs a decade and hundreds of crores just for paperwork. The inner wall — the one the market keeps mispricing — lives inside the Venus Medicine Research Centre (VMRC). A DSIR-recognised in-house lab generating 135 global patents across the US, EU, and India. The core breakthrough: proprietary Antibiotic Adjuvant Entities — molecules that don't just treat infections, they disarm the bacterial resistance mechanism itself. The flagship Elores shields antibiotics from the beta-lactamase and carbapenemase enzymes bacteria use to neutralise them. Management — why trust them Two reasons: tested under pressure, and kept their word. Dr Manu Chaudhary (Joint MD, PhD structural biology) personally anchors the 135 patent portfolio — a promoter-scientist who built the core moat. Pawan Chaudhary (MD) architected the commercial pivot. Saransh Chaudhary (next-gen, CEO Venusiac) now drives global out-licensing of Elores. Promoters hold 41.76% equity with zero shares pledged. When debt was heavy and commercialisation was stalling, management did not dilute equity, did not diversify — they paid down every rupee from operations. FY26 net profit: ₹102.78 Cr, up 127% YoY. Under-promise, over-deliver. Current numbers and EPS trajectory FY26 actuals: Sales ₹769.6 Cr · EBITDA margin 18.5% · PAT ₹102.8 Cr · EPS ₹76.9 · ROIC 21.8% · CFO ₹155 Cr — cash conversion 1.5× reported profit. Base-case model at 15–18% guided revenue growth: FY27E EPS ₹91.7 · FY28E EPS ₹128.7. At CMP ₹1,610, that is 12.5× forward P/E on FY28E — priced as if it is still the debt-heavy generic manufacturer of five years ago. The asymmetric bet — four levers and why now Most estimates only capture revenue growth. The real asymmetry is what happens when product mix shifts toward high-margin, IP-protected molecules. 1. Mix shift: generic → proprietary IP drugs — the highest-probability lever and the most direct EPS driver. Venus sells a blend of commodity generics (gross margin ~28–30%) and proprietary patented formulations like Elores (gross margin ~45–50% ). As Elores scales deeper into hospital formularies, every 5% revenue mix shift adds ~150–200 bps EBITDA margin. On just 1.33 Cr shares, each 100 bps margin expansion = ~₹5–6 EPS uplift. If EBITDA exits at 26–28% instead of 22.5%, FY28E EPS reaches ₹155–170 — not ₹128. 2. Global Elores out-licensing milestones — Venus already received a ₹11 Cr milestone payment from one AMR licensing deal. Each EU or US agreement adds upfront fees plus multi-year royalties — zero incremental capex. Two or three deals could add ₹15–25 Cr PAT annually, translating to ₹11–19 EPS purely from licensing income. 3. AMR becomes a global policy emergency — WHO, G7, and EU have flagged antimicrobial resistance as a tier-1 crisis. Fast-track procurement frameworks for proven AMR therapies are being legislated now. Venus is one of the very few companies globally with commercially validated, patented, adjuvant-based AMR solutions already in 60 countries — a potential strategic acquisition target for Big Pharma missing this platform entirely. 4. Plerixafor oncology inflection — entry into the $65B → $105B chemo injectable market via GCC and EU hospital formularies. EU-GMP manufacturing and regulatory filings are already in place. Adoption is a matter of when, not whether. ⚡ Why now — five reasons the window is open today → Balance sheet inflection just happened. The debt paydown that unlocks all future optionality was completed in FY26. You are evaluating this in the first year of a clean, self-funding capital structure → Capacity expansion is being commissioned now. The ₹65 Cr Baddi lyophilisation line — which raises the revenue ceiling from ₹850 Cr to ₹1,150 Cr — goes live in Q2 FY27. The earnings impact will show up in the next 2–3 quarters. → Mix shift is at its earliest visible stage. EBITDA expanded from 12% to 18.5% in a single year as patented molecules grew faster than generics. The inflection has started . At 22–28% EBITDA, this is a completely different earnings machine. → Global AMR policy is accelerating. The EU's AMR Action Plan and the US PASTEUR Act are moving from discussion to legislation in 2025–26. Governments are creating guaranteed procurement frameworks for validated AMR drugs — and Elores is one of the very few that qualifies today. → Valuation has not caught up (or has it ??). At 12.5× FY28E on a debt-free, 21% ROIC, IP-protected business with an expanding moat — the stock is priced for a generic compounder's destiny, not a specialty pharma platform's (it may be totally wrong to interpret this way). Venus Remedies is an IP-protected, debt-free, founder-scientist-run specialty pharma company at 12.5× FY28E earnings. The base case already works. The mix-shift toward proprietary molecules is already happening and unpriced. The licensing optionality, AMR tailwind, and oncology expansion sit on top as free options. The window is open because the balance sheet cleared last year and the capacity expansion fires next quarter. Is the market still seeing a debt-laden generic injectable manufacturer from five years ago — or has it simply not looked closely enough at what is quietly being built inside? [Not investment advice, DYOR]

Maxvolt Energy Industries Ltd: Powering India’s Unregistered EV & Aggressive Shift into Circular Battery Economies open.substack.com/pub/suren2…

Sakar Healthcare Ltd - Q4FY26 | Concall Insights Financial Highlights •Q4FY26 revenue from operations grew 42% YoY to ₹71.1 crore •FY26 revenue increased strongly to ₹251.7 crore versus ₹177.6 crore in FY25 •Q4FY26 EBITDA increased 67% YoY to ₹26.2 crore with EBITDA margin at 37% •FY26 EBITDA grew 39% YoY to ₹68.9 crore •Q4FY26 PAT grew 91% YoY to ₹11 crore •FY26 PAT increased 74% YoY to ₹30.5 crore •Gross margins remained healthy at 60% driven by operational efficiencies and oncology scale-up •Management expects margins to sustain and improve further with rising oncology contribution Oncology Business Growth •Oncology business contributed 38% of FY26 revenue versus 21% in FY25 •Q4FY26 oncology revenue stood at ₹31.5 crore •Company targets doubling oncology revenues over next two years •Management aims to achieve ₹500 crore revenue milestone within two years driven primarily by oncology •Long-term oncology-led revenue potential from Bavla facility estimated at ₹800 crore-₹1,000 crore at optimal utilization •Oncology exports expected to become dominant growth driver over medium term Exports & International Expansion •Company positioning itself as a pure-play export-led oncology player •Exports already underway to UK, Mauritius, Lebanon, Algeria and African markets •Accord Healthcare UK approved Imatinib manufacturing for European supplies •More than 60 oncology business contracts signed with 35 ongoing discussions globally •125 dossiers filed globally out of 250 dossiers shared, with 12 marketing authorizations received •Company targets 300 dossier approvals and 100 overseas business contracts over next two years •Management expects oncology exports and domestic oncology sales to become nearly equal during FY27 Partnerships & Technology Transfers •Technology transfer projects ongoing with Accord, Intas, Torrent, Emcure, Glenmark and Zydus •Accord-Intas portfolio includes 10 oncology products with revenue opportunity of ₹50 crore-₹100 crore •Five tech transfer projects for Europe and UK already commercializing from Q1FY27 •Seven additional Accord products under regulatory approval pipeline for Europe •Management expects strong export commercialisation from Q2FY27 onwards •Commercial supplies from tech transfer projects expected to significantly accelerate oncology growth Capacity Utilization & Manufacturing •EU-GMP approved Bavla oncology facility designed for regulated global markets •Facility supports oral solids, injectables, oral liquids and oncology APIs •Current oncology plant utilization remains below 30%, leaving strong operating leverage potential •Management expects utilization to improve to 50%-55% over next two years •Long-term expansion achievable without significant incremental capex •API integration progressing with 21 in-house cytotoxic APIs developed Regulatory & Product Pipeline •11 approvals received for key oncology molecules including Imatinib, Abiraterone, Capecitabine and Gemcitabine •Two CEP approvals already received for Gefitinib and Capecitabine APIs •Additional API approvals under process for regulated markets •31 oncology dossiers currently under registration globally •Company expects significant commercialization of registered products during FY27 •Regulatory approvals and technology transfers validating Sakar’s manufacturing and compliance capabilities Guidance & Strategy •Management targeting ~40% revenue growth in FY27 •Oncology expected to remain key growth engine for next several years •Long-term revenue mix target is 60% oncology and 40% non-oncology •Within oncology, target mix is 65% exports and 35% domestic •Focus remains on increasing dossier approvals, expanding international partnerships and scaling regulated market launches •Company expects EBITDA margins in oncology division to sustain at 25%-30% over medium term

Sakar Share the first MA of oncology injection product of Sakar in EU.This approval signifies a significant milestone in Sakar Healthcare's international expansion, enabling the company to enter the European oncology market.

Self note : Sacheerome - #Sacheerome Top notch customers: ITC,Dabur,Emami,Cavinkare, Himalaya Listed at an attractive valuations 20x ,Debt free,operationally efficient 3.6x expansion to be operational from Q4 FY26. Less competition= scarcity premium

Purple United -Concall Future looks bright Management-In next 2 yrs v can easily double our rev 100% on YoY basis Targeting 200stores in fy27 Fy25-43stores Fy26-111stores Employee count has grown by more than 250% in last one yr Full Concall here youtu.be/6rjQcb-Ilzc?si=vRTO…

Quality Power Proxy Play to Power , Renewables , AI & Data Center Themes Solid Q4 FY 26 Management had guided for nearly ₹900 Cr topline and ~22% EBITDA margins, but the company delivered nearly ₹1000 Cr topline with ~24% EBITDA margins. A lot of people are saying margins have fallen, but they are not understanding the results properly. The issue is mainly due to the Turkey subsidiary (Endoks), where hyperinflation accounting created a loss impact. Adjusting that, EBITDA and PAT would have been even better. So overall, margins are completely fine and management has clearly walked the talk. Now the key thing to watch will be their commentary on data center-related orders in the concall. At current numbers, TTM PE comes around ~44x if you adjust the Turkey hyperinflation loss (~₹26 Cr). Another positive thing is that the company turned PAT positive in FY25 despite all these issues. Most people on Twitter do not know how to properly read results. No recommendation. @compoundingaiin